跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
海乐卫 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Eribulin Mesilate Injection
Approved
化学药品
Eribulin Mesilate Injection
Eisai Europe Ltd
🇨🇳 National Medical Products Administration
Approval Date
Jul 12, 2019
Approval ID
7uctI7X4dAg
Company
Eisai Europe Ltd
Type
化学药品
Approval Details
Approval Id
7uctI7X4dAg
Approval Number
H20190042
Generic Name
甲磺酸艾立布林注射液
Generic Name En
Eribulin Mesilate Injection
Brand Name
海乐卫
Drug Type
化学药品
Dosage Form
注射剂
Strength
2ml:1mg
Reg Date
2019-07-12
Expired Date
2024-07-11
Company Name
Eisai Europe Ltd
Company Address
European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire AL10 9SN, United Kingdom
Production Company Name
BSP PHARMACEUTICALS SPA
Production Company Address
Via Appia Km 65,561 (loc. Latina Scalo), 04013 Latina (LT), Italy
Company Detail Path
/organization/eisai-europe-ltd
Production Company Detail Path
/organization/bsp-pharmaceuticals-spa
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Jul 12, 2019
Approval ID
7uctI7X4dAg
Type
化学药品
Back to NMPA Approvals